Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16415760 | 0.80 | MEN1 (0.52) | MAPTL3MBTL1MAPK1TDP1SMN1; SMN2 | |
| SCHEMBL2675108 | 0.80 | LTA4H (0.58) | MAPTL3MBTL1MAPK1TDP1MAPK14 | |
| SCHEMBL24992521 | 0.78 | USP28 (0.43) | MAPTL3MBTL1MAPK1TDP1MAPK14 | |
| SCHEMBL29687741 | 0.77 | L3MBTL1 (0.45) | L3MBTL1MAPK1MAPK14ALOX5HTT | |
| SCHEMBL24455273 | 0.77 | L3MBTL1 (0.45) | L3MBTL1MAPK1MAPK14ALOX5HTT | |
| SCHEMBL721575 | 0.76 | MAOB (0.45) | MAPTL3MBTL1MAPK1TDP1SMN1; SMN2 | |
| SCHEMBL24228010 | 0.76 | SMN1; SMN2 (0.51) | MAPTL3MBTL1MAPK1TDP1MAPK14 | |
| SCHEMBL19107560 | 0.76 | RAB9A (0.45) | MAPTL3MBTL1MAPK1TDP1MAPK14 | |
| SCHEMBL30108290 | 0.76 | MAPT (0.41) | MAPTL3MBTL1MAPK1TDP1MAPK14 | |
| SCHEMBL601741 | 0.76 | FOLH1 (0.50) | L3MBTL1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240199576-A1 | NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-06-20 | — | — | US | disclosed |
| CN-118119609-A | Imidazole derivatives and their use as antibiotics | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4370514-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-4313042-A1 | NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117120053-A | Novel cyclopenta [ c ] pyrrole NR2B negative allosteric modulators | 诺华股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| CN-115557946-A | Heterocyclic lactam compound, pharmaceutical composition containing same and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022204337-A1 | NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | MAPT 4201/4885L3MBTL1 2206/4885MAPK1 2104/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | MAPT 4201/4885L3MBTL1 2206/4885MAPK1 2104/4885 |
| US-20240199576-A1 | NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | GRIN2C, GRIN2B, GRIN2A | MAPT 1195/4885L3MBTL1 4814/4885MAPK1 934/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | MAPT 4094/4885L3MBTL1 2450/4885MAPK1 2146/4885 |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | F12, C1R, MRPL21 | MAPT 4201/4885L3MBTL1 2206/4885MAPK1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.